Shire Given Conviction-Buy Rating at Goldman Sachs Group Inc. (SHP)
Shire (LON:SHP)‘s stock had its “conviction-buy” rating restated by equities researchers at Goldman Sachs Group Inc. in a research report issued on Monday, Stock Ratings News reports.
SHP has been the subject of a number of other recent research reports. Analysts at BNP Paribas reiterated an “outperform” rating on shares of Shire in a research note to investors on Wednesday, October 2nd. They now have a GBX 2,700 ($43.32) price target on the stock. Separately, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Shire in a research note to investors on Tuesday, October 1st. Finally, analysts at JPMorgan Chase & Co. upgraded shares of Shire from a “neutral” rating to an “overweight” rating in a research note to investors on Monday, September 30th. They now have a GBX 3,000 ($48.13) price target on the stock, up previously from GBX 2,270 ($36.42). One investment analyst has rated the stock with a sell rating, five have given a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of GBX 2,025.49 ($32.50).
Shares of Shire (LON:SHP) opened at 2436.00 on Monday. Shire has a 1-year low of GBX 1682.00 and a 1-year high of GBX 2602.00. The stock has a 50-day moving average of GBX 2432.08 and a 200-day moving average of GBX 2167.18. The company’s market cap is £13.388 billion.
Shire plc (LON:SHP) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.